Baxter cleared from DoJ antitrust saline probe

This article was originally published here


Baxter (NYSE:BAX) said yesterday that it has been cleared from a U.S. Dept. of Justice antitrust probe, launched in 2017, investigating companies that market intravenous saline solutions.

The probe came as hospitals endured a shortage of intravenous saline solutions, which are used to hydrate hospital patients. The shortage dates back to late 2013, after drugmakers told hospitals they might experience delays in deliveries of saline.

 Read the whole story on our sister site, Drug Delivery Business News

The post Baxter cleared from DoJ antitrust saline probe appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply